Zai Lab Reports Third-Quarter Revenue of $108.21M and EPS Loss of $0.04
Third-quarter revenue fell 7% year over year and the net loss widened. Lower sales of ZEJULA, OPTUNE and VYVGART outweighed growth in NUZYRA and XACDURO and KarXT’s June launch; higher product costs and research and development spending also weighed on results.
Zai Lab’s third-quarter revenue declined 7% year over year, while its net loss widened. Lower ZEJULA, OPTUNE and VYVGART sales outweighed growth in NUZYRA and XACDURO and the June launch of KarXT; higher product costs and research and development spending also weighed on operating results.Financial…